TD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Ovid Therapeutics (OVID – Research Report). The company’s shares closed yesterday at $3.23.

According to TipRanks, Baral is a 4-star analyst with an average return of 6.5% and a 43.18% success rate. Baral covers the Healthcare sector, focusing on stocks such as Neurogene, Milestone Pharmaceuticals, and COMPASS Pathways.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ovid Therapeutics with a $7.92 average price target, implying a 145.20% upside from current levels. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $7.00 price target.

Based on Ovid Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $141.6 thousand and a GAAP net loss of $15.32 million. In comparison, last year the company earned a revenue of $46.3 thousand and had a GAAP net loss of $11.5 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ovid Therapeutics (OVID) Company Description:

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.